ClinicalTrials.gg
CompletedNCT06109415AMAZEUpdated Oct 27, 2026Results posted

Cohort 1 (TSA) of: A Multi-surgery Assessment of ZYNRELEF (HTX-011)

A Phase 4 interventional study of HTX-011 and Bupivacaine Hydrochloride in Postoperative Pain, Total Shoulder Arthroplasty and Multimodal Analgesia, sponsored by Heron Therapeutics. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Heron Therapeutics · Phase 4, Interventional, and Prevention

From the registry’s dates

  • Registered 2 years after the study started (first participant enrolled Oct 2021, registered Oct 2023).
Updated Oct 27, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 364 studies testing bupivacaine in Pain, Postoperative — 57 open to participants now, 60 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.

Enrollment
310th of 364
30 · median 70
Started
2021
with 30 others
Phase 4
133 of 364
18 open now
Registered
283rd of 364
by date
Lead sponsor
17 of 364
Heron Therapeutics

Among the 364 studies testing bupivacaine in Pain, Postoperative, this one is the 310th largest by enrollment, is one of 31 that started in 2021, is one of 133 in phase 4, and was the 283rd registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

57 of the 364 studies testing bupivacaine in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About bupivacaine

Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 364 studies testing bupivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

Cohort 1 (subjects undergoing total shoulder arthroplasty, TSA) of a Phase 4, randomized, blinded, active-controlled, multicohort study to evaluate HTX-011 compared with bupivacaine HCl in subjects undergoing different surgical procedures.

See also the separate record for the master study protocol (NCT05109312).

Read the detailed description

Subjects were randomized in a 2:1 ratio to have either HTX-011 400 mg/12 mg or bupivacaine HCl 100 mg administered into the surgical site prior to closure. Subjects and study site personnel performing postoperative safety and pharmacodynamic (PD) assessments were blinded to treatment assignments; however, unblinded study site staff were permitted to collect samples for pharmacokinetic (PK) analysis.

During surgery, in addition to study drug (HTX-011 or bupivacaine HCl), subjects could receive intravenous (IV) fentanyl, and all subjects were to receive a single dose of either IV morphine or IV hydromorphone just prior to the application of dermal sutures.

Subjects remained in the facility through 72 hours post-dose for safety, PK, and PD assessments. Subjects received a scheduled non-opioid multimodal analgesic (MMA) regimen throughout the 72-hour postoperative period consisting of oral (PO) acetaminophen 1 g every 8 hours (q8h) alternating with PO ibuprofen 400 mg q8h.

After discharge, subjects were to continue their scheduled MMA regimen through Day 7 and complete the daily diary to record opioid use through the Day 15 Visit.

PK sampling occurred through Day 7. For subjects with drains, all drainage fluid was to be collected and pooled over 12-hour intervals (±1 hour) through 72 hours post-dose for potential measurement of the concentrations of bupivacaine, meloxicam, and other ZYNRELEF components.

During the 72-hour postoperative period, subjects were to receive rescue medication only upon subject request for treating postoperative pain. Prior to administration of the first dose of rescue medication, if the subject had not already had at least 1 postoperative pain score assessed, then a numeric rating scale (NRS) of pain intensity at rest (NRS-R) score was to be obtained, followed by an NRS of pain intensity with activity (NRS-A) score.

If a subject had not received any opioids or received \<5 IV morphine milligram equivalents (MME; eg, \<10 mg of oxycodone) within 12 hours prior to discharge, the subject was not to receive an opioid prescription at discharge. If a subject had received ≥5 IV MME within 12 hours prior to discharge, the Investigator could provide the subject with a prescription for PO immediate-release oxycodone tablets: no more than twenty 5 mg immediate-release oxycodone, take 1 to 2 pills (5 to 10 mg) every 4 hours as needed.

03

Conditions studied

  • Postoperative Pain
  • Total Shoulder Arthroplasty
  • Multimodal Analgesia

Browse trials for

Keywords

  • postoperative pain
  • total shoulder arthroplasty
  • multimodal analgesia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has (ASA) Physical Status of I, II, or III.
  • Is scheduled to undergo a unilateral Total Shoulder Arthroplasty.

Exclusion criteria

Exclusion Criteria:

  • Is undergoing a revision surgery.
  • Has a known or suspected history of or idiosyncratic reaction to bupivacaine (or other local anesthetics), NSAIDs, acetaminophen, oxycodone, morphine, or hydromorphone.
  • History of severe allergic reaction to aspirin or other NSAIDs, or known history of severe gastrointestinal adverse reactions associated with NSAID use.
  • Has taken meloxicam within 10 days prior to the scheduled surgery, or any NSAID within 24 hours prior to the scheduled surgery, with the exception of subjects on low-dose (≤100 mg) daily acetylsalicylic acid for cardioprotection.
  • Opioid use for most days within the last 3 months prior to Screening in the opinion of the Investigator.
  • Has been administered immediate-release bupivacaine HCl within 5 days prior to the scheduled surgery, or a modified-release bupivacaine product within 14 days prior to the scheduled surgery.
  • Has initiated treatment with any of the following medications within 1 month prior to study drug administration: selective serotonin reuptake inhibitors, selective norepinephrine reuptake inhibitors, gabapentin, pregabalin, duloxetine, or cyclooxygenase-2 inhibitors.
  • Has been administered systemic within 5 half-lives or 10 days prior to the scheduled surgery (whichever is longer).
  • Has a known or suspected history of drug abuse, a positive drug screen (except for cannabinoids) on the day of surgery, or a history of alcohol abuse within the past 5 years.
  • Suspected or confirmed active coronavirus disease 2019 (COVID-19) infection.
  • Had a in the last year, with the exception of nonmetastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.
  • Has undergone 3 or more surgeries within 12 months, other than for diagnostic procedures (eg, colonoscopy).
  • Has a (BMI) >40 kg/m2.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    HTX-011 + MMA

    HTX-011 400 mg/12 mg via instillation + oral (PO) multimodal analgesic (MMA) regimen

    Drug: HTX-011 · Drug: MMA regimen · Device: ZYNRELEF kit components for administration

  • Active comparator
    Bupivacaine HCl + MMA

    Bupivacaine HCl 100 mg via injection + oral (PO) multimodal analgesic (MMA) regimen

    Drug: Bupivacaine Hydrochloride · Drug: MMA regimen

Interventions

  • DrugHTX-011

    Drug pages: Bupivacaine · Meloxicam

    HTX-011 (bupivacaine/meloxicam) extended-release solution for instillation use, supplied in commercially available ZYNRELEF kits

    Also known as: ZYNRELEF

  • bupivacaine HCl (without epinephrine) 0.25%

  • DrugMMA regimen

    Drug pages: Acetaminophen · Ibuprofen

    acetaminophen 1 g q8h every 8 hours (q8h) and ibuprofen 400 mg q8h, alternating the 2 medications so that an analgesic was taken approximately every 4 hours (q4h)

    Also known as: acetaminophen, ibuprofen

  • DeviceZYNRELEF kit components for administration

    ZYNRELEF kits include sterile, individually packaged components for administration, including vented vial spikes, Luer lock syringes, custom Luer lock applicators, and syringe tip caps.

06

What researchers measure

Primary outcomes

  1. Incidence of TEAEs

    Incidence of treatment-emergent adverse events

    Time frame: Through Day 15

Secondary outcomes

  1. Cmax

    Maximum concentration of bupivacaine

    Time frame: Through 144 hours

  2. Tmax

    Time of occurrence of maximum concentration of bupivacaine

    Time frame: Through 144 hours

  3. AUClast

    Area under the concentration-time curve from Time 0 to the time of the last quantifiable concentration of bupivacaine

    Time frame: Through 144 hours

  4. AUCinf

    Area under the concentration-time curve from Time 0 extrapolated to infinity of bupivacaine

    Time frame: Through 144 hours

  5. t½

    Apparent terminal half-life of bupivacaine

    Time frame: Through 144 hours

07

Results

Posted Oct 27, 2026

Participant flow

Participant flow — Overall Study
MilestoneHTX-011 + MMABupivacaine HCl + MMA
Started2010
Completed2010
Not completed00

Outcome measures

PrimaryIncidence of TEAEs

Incidence of treatment-emergent adverse events

Time frame:
Through Day 15
Reported as:
Count of participants · Participants
Incidence of TEAEs
ParticipantsHTX-011 + MMABupivacaine HCl + MMA
Incidence of TEAEs187
SecondaryCmax

Maximum concentration of bupivacaine

Time frame:
Through 144 hours
Reported as:
Mean · ng/mL
Cmax
ng/mLHTX-011 + MMABupivacaine HCl + MMA
Cmax372 ± 165398 ± 288
SecondaryTmax

Time of occurrence of maximum concentration of bupivacaine

Time frame:
Through 144 hours
Reported as:
Median · hours
Tmax
hoursHTX-011 + MMABupivacaine HCl + MMA
Tmax20.12 (1.82 to 48.20)0.58 (0.50 to 2.77)
SecondaryAUClast

Area under the concentration-time curve from Time 0 to the time of the last quantifiable concentration of bupivacaine

Time frame:
Through 144 hours
Reported as:
Mean · h∙ng/mL
AUClast
h∙ng/mLHTX-011 + MMABupivacaine HCl + MMA
AUClast20500 ± 119004280 ± 1820
SecondaryAUCinf

Area under the concentration-time curve from Time 0 extrapolated to infinity of bupivacaine

Time frame:
Through 144 hours
Reported as:
Mean · h∙ng/mL
AUCinf
h∙ng/mLHTX-011 + MMABupivacaine HCl + MMA
AUCinf20500 ± 119004320 ± 1820
Secondaryt½

Apparent terminal half-life of bupivacaine

Time frame:
Through 144 hours
Reported as:
Mean · hours
t½
hoursHTX-011 + MMABupivacaine HCl + MMA
t½10.4 ± 2.467.51 ± 3.00

Adverse events

Collected over Through Day 15. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HTX-011 + MMA0/20 (0%)0/20 (0%)18/20 (90%)
Bupivacaine HCl + MMA0/10 (0%)0/10 (0%)7/10 (70%)
Most frequent other events
Showing 10 of 31
Most frequent other events
EventHTX-011 + MMABupivacaine HCl + MMA
ConstipationGastrointestinal disorders6/200/10
NauseaGastrointestinal disorders3/203/10
DizzinessNervous system disorders5/202/10
HeadacheNervous system disorders1/202/10
HypoxiaRespiratory, thoracic and mediastinal disorders1/201/10
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/201/10
VomitingGastrointestinal disorders1/201/10
Muscle spasmsMusculoskeletal and connective tissue disorders0/201/10
Oedema peripheralGeneral disorders0/201/10
PyrexiaGeneral disorders0/201/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)HTX-011 + MMABupivacaine HCl + MMATotal
Mean67.9 ± 8.0570.1 ± 9.6168.6 ± 8.50
Sex: Female, Male
Sex: Female, Male(Participants)HTX-011 + MMABupivacaine HCl + MMATotal
Female538
Male15722
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)HTX-011 + MMABupivacaine HCl + MMATotal
Hispanic or Latino000
Not Hispanic or Latino201030
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)HTX-011 + MMABupivacaine HCl + MMATotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White191029
More than one race101
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)HTX-011 + MMABupivacaine HCl + MMATotal
United States201030
08

Study locations

5 sites
  • Woodland International Research Group, LLC
    Little Rock, Arkansas 72211, United States
  • Center for Orthopaedic Reconstruction and Excellence
    Jenks, Oklahoma 74037, United States
  • First Surgical Hospital
    Bellaire, Texas 77401, United States
  • Legent Orthopedic Hospital
    Carrollton, Texas 75006, United States
  • JBR Clinical Research
    Salt Lake City, Utah 84107, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Jul 2022, 8 months.

Results were first posted in Oct 2026, 4 years 3 months after primary completion.

Of 542 phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2023
First posted
Oct 31, 2023
StartActual
Oct 20, 2021
Primary completionActual
Jul 18, 2022
CompletionActual
Jul 29, 2022
Results first posted
Oct 27, 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 27, 2026
Interventions
Added Drug: MMA regimen·Device: ZYNRELEF kit components for administration; removed Drug: Ibuprofen·Drug: Acetaminophen·Device: Luer lock applicator. Arms added: HTX-011 + MMA·Bupivacaine HCl + MMA; arms removed: Treatment Group 1 Cohort 1·Treatment Group 2 Cohort 1
Oct 27, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Incidence of treatment-emergent adverse events (TEAEs).Now Incidence of TEAEsTime frame: Through Day 15
Oct 27, 2026
Documents
Secondary outcomes
5 added, 5 removed
What changed in the outcomes
  • AddedCmaxTime frame: Through 144 hours
  • AddedTmaxTime frame: Through 144 hours
  • AddedAUClastTime frame: Through 144 hours
  • AddedAUCinfTime frame: Through 144 hours
  • Addedt½Time frame: Through 144 hours
  • RemovedMaximum concentration (Cmax) of bupivacaine and meloxicamTime frame: Through 144 hours
  • RemovedTime of occurrence of maximum concentration (Tmax) of bupivacaine and meloxicamTime frame: Through 144 hours
  • RemovedArea under the concentration-time curve from Time 0 to the time of the last quantifiable concentration (AUClast) of bupivacaine and meloxicamTime frame: Through 144 hours
  • RemovedArea under the concentration-time curve from Time 0 extrapolated to infinity (AUCinf) of bupivacaine and meloxicamTime frame: Through 144 hours
  • RemovedApparent terminal half-life (t½) of bupivacaine and meloxicamTime frame: Through 144 hours
Oct 27, 2026
Title
Cohort 1 (TSA) of: A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE.
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Incidence of treatment-emergent adverse events (TEAEs).Now Incidence of TEAEsTime frame: Through Day 15
    Secondary outcomes 5 added, 5 removed
    What changed in the outcomes
    • AddedCmaxTime frame: Through 144 hours
    • AddedTmaxTime frame: Through 144 hours
    • AddedAUClastTime frame: Through 144 hours
    • AddedAUCinfTime frame: Through 144 hours
    • Addedt½Time frame: Through 144 hours
    • RemovedMaximum concentration (Cmax) of bupivacaine and meloxicamTime frame: Through 144 hours
    • RemovedTime of occurrence of maximum concentration (Tmax) of bupivacaine and meloxicamTime frame: Through 144 hours
    • RemovedArea under the concentration-time curve from Time 0 to the time of the last quantifiable concentration (AUClast) of bupivacaine and meloxicamTime frame: Through 144 hours
    • RemovedArea under the concentration-time curve from Time 0 extrapolated to infinity (AUCinf) of bupivacaine and meloxicamTime frame: Through 144 hours
    • RemovedApparent terminal half-life (t½) of bupivacaine and meloxicamTime frame: Through 144 hours
    Interventions Added Drug: MMA regimen·Device: ZYNRELEF kit components for administration; removed Drug: Ibuprofen·Drug: Acetaminophen·Device: Luer lock applicator. Arms added: HTX-011 + MMA·Bupivacaine HCl + MMA; arms removed: Treatment Group 1 Cohort 1·Treatment Group 2 Cohort 1
    Title Cohort 1 (TSA) of: A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE.
    + 5 other changes: index terms, oversight details, description, conditions and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06109415
Lead sponsor
Heron Therapeutics
Responsible party
Sponsor
First posted
Oct 31, 2023
Start date
Oct 20, 2021
Primary completion
Jul 18, 2022
Completion
Jul 29, 2022
Results posted
Oct 27, 2026
Last update
Oct 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bupivacaine · Meloxicam

Start the discussion